We came across a bullish thesis on Johnson & Johnson (NYSE:JNJ) on Business Model Mastery Substack by The Antifragile Investor. In this article, we will summarize the bulls’ thesis on JNJ. Johnson & Johnson (NYSE:JNJ)’s share was trading at $146.23 as of Jan 7th. JNJ’s trailing and forward P/E were 24.17 and 13.76 respectively according to Yahoo Finance.
A medical technician using surgical robotics to perform minimally-invasive urologic surgery in an operating room.
Johnson & Johnson (NYSE:JNJ), a global healthcare leader, is undergoing a strategic transformation to solidify its dominance in an ever-evolving industry. With a forward P/E ratio of 14.5, low debt levels, and a dividend yield exceeding 3%, the company presents a compelling investment opportunity. Analysts forecast over 5% annual EPS growth, driven by J&J’s sharpened focus on Innovative Medicine and MedTech—two sectors poised for long-term growth amid rising global healthcare demands.
In 2023, J&J restructured its business by spinning off its Consumer Health division, allowing it to concentrate on high-margin, innovation-driven segments. Innovative Medicine, the rebranded Pharmaceuticals division, continues to thrive, contributing significantly to revenue through blockbuster drugs like STELARA and DARZALEX. Together, oncology and immunology account for over 45% of pharmaceutical sales, underscoring their strategic importance. MedTech, encompassing cutting-edge medical devices in orthopedics, vision care, and surgery, now generates 44% of J&J’s revenue, with products like ACUVUE lenses and Ethicon surgical tools driving robust growth. This narrowed focus enables J&J to cater effectively to an aging population and the increasing prevalence of chronic diseases.
J&J’s global footprint further strengthens its resilience. Nearly half of its revenue comes from North America, benefiting from advanced healthcare systems and substantial R&D investment. Europe, contributing 22%, is a growth hub for oncology and MedTech innovations, while the Asia-Pacific region, at 15%, offers expanding opportunities in emerging markets. This geographical and customer diversity shields J&J from risks like regional regulatory changes or temporary dips in elective procedures.
The company’s financial success is anchored in high-margin biologics and premium MedTech solutions. In 2023, oncology revenue surged by 14.6%, with DARZALEX and ERLEADA leading the charge. Immunology drugs like STELARA and TREMFYA also posted strong gains, delaying generic competition until 2025 or beyond. Meanwhile, MedTech innovations, including robotic-assisted surgical tools and Biosense Webster’s electrophysiology devices, saw heightened demand as elective surgeries resumed post-pandemic. J&J’s ability to command premium pricing for these products underscores its competitive edge.
Despite challenges such as patent expirations and regulatory pressures, J&J’s substantial R&D investments and operational efficiencies mitigate risks. By leveraging trends in biologics, wearable devices, and robotics, the company is well-positioned to expand its market share. For investors, J&J offers an attractive blend of stability, growth, and financial strength, making it a standout in the fast-paced healthcare sector.
Johnson & Johnson (NYSE:JNJ) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 81 hedge fund portfolios held JNJ at the end of the third quarter which was 80 in the previous quarter. While we acknowledge the risk and potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than JNJ but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure: None. This article was originally published at Insider Monkey.